434 results on '"Abidi, Muneer"'
Search Results
2. Engraftment Day Electrolytes and Hydration and the Risk of Atrial Fibrillation Early after Hematopoietic Stem Cell Transplant
3. Abatacept with FluBu2: To Use or Not to Use
4. Standard Risk Assessment Tools Fall Short to Assess Risk in Transplant Patients
5. Collection of Peripheral Blood Progenitor Cells in 1 Day Is Associated with Decreased Donor Toxicity Compared to 2 Days in Unrelated Donors
6. Risk of acute myeloid leukemia and myelodysplastic syndrome after autotransplants for lymphomas and plasma cell myeloma
7. Calcineurin and mTOR Inhibitor–Free Post-Transplantation Cyclophosphamide and Bortezomib Combination for Graft-versus-Host Disease Prevention after Peripheral Blood Allogeneic Hematopoietic Stem Cell Transplantation: A Phase I/II Study
8. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial
9. Maintenance versus Induction Therapy Choice on Outcomes after Autologous Transplantation for Multiple Myeloma
10. Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT)
11. Patient-Reported Outcomes and Socioeconomic Status as Predictors of Clinical Outcomes after Hematopoietic Stem Cell Transplantation: A Study from the Blood and Marrow Transplant Clinical Trials Network 0902 Trial
12. Post-Transplant Outcomes in High-Risk Compared with Non–High-Risk Multiple Myeloma: A CIBMTR Analysis
13. Modeling Risk of Atrial Fibrillation in Stem Cell Transplant
14. A Single Institution Randomized Clinical Trial Evaluating Ciprofloxacin Versus Levofloxacin As Antibacterial Prophylaxis for Patients Receiving Hematopoietic Stem Cell Transplantation
15. Targeting CD138−/CD20+ Clonogenic Myeloma Precursor Cells Decreases These Cells and Induces Transferable Antimyeloma Immunity
16. Significant Improvements in the Practice Patterns of Adult Related Donor Care in US Transplantation Centers
17. Analysis of the Effect of Race, Socioeconomic Status, and Center Size on Unrelated National Marrow Donor Program Donor Outcomes: Donor Toxicities Are More Common at Low-Volume Bone Marrow Collection Centers
18. BEAM Conditioning Regimen Has Higher Toxicity Compared With High-Dose Melphalan for Salvage Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma
19. Hematopoietic Stem Cell Transplantation for Multiple Myeloma: Guidelines from the American Society for Blood and Marrow Transplantation
20. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial
21. Impact of Pretransplant Therapy and Depth of Disease Response before Autologous Transplantation for Multiple Myeloma
22. Incidence, Risk Factors, and Outcome of Cytomegalovirus Viremia and Gastroenteritis in Patients with Gastrointestinal Graft-versus-Host Disease
23. Renal Toxicity with Carfilzomib in Multiple Myeloma: Secondary Analysis of SWOG S1304 Comparing Low-Dose Versus High-Dose Carfilzomib
24. Older Patients with Myeloma Derive Similar Benefit from Autologous Transplantation
25. Exercise and Stress Management Training Prior to Hematopoietic Cell Transplantation: Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0902
26. High Incidence of Severe Acute Graft-Versus-Host Disease with Tacrolimus and Mycophenolate Mofetil in a Large Cohort of Related and Unrelated Allogeneic Transplantation Patients
27. CD20-Targeted T Cells after Stem Cell Transplantation for High Risk and Refractory Non-Hodgkin's Lymphoma
28. Salvage Second Hematopoietic Cell Transplantation in Myeloma
29. A Phase I Dose-Escalation Trial of High-Dose Melphalan with Palifermin for Cytoprotection Followed by Autologous Stem Cell Transplantation for Patients with Multiple Myeloma with Normal Renal Function
30. Anti-Thymocyte Globulin (Thymoglobulin), Tacrolimus, and Sirolimus as Acute Graft-versus-Host Disease Prophylaxis for Unrelated Hematopoietic Stem Cell Transplantation
31. Melphalan 180 mg/m2 Can Be Safely Administered As Conditioning Regimen before an Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma Patients with Creatinine Clearance 60 mL/min/1.73 m2 or Lower with Use of Palifermin for Cytoprotection: Results of a Phase I Trial
32. Poor Humoral Response to Sars-Cov-2 Vaccination Early after Hematopoietic Cell Transplantation: Interim Results of Prospective Study (NCT04723706)
33. GCSF Dilemma: To Give or Not to Give with ATG?
34. Patient-reported physical functioning predicts the success of hematopoietic cell transplantation (BMT CTN 0902)
35. Outcome of Patients With IgD and IgM Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplantation: A Retrospective CIBMTR Study
36. Clinical and Ultrasonic Evaluation of Spleen Size during Peripheral Blood Progenitor Cell Mobilization by Filgrastim: Results of an Open-Label Trial in Normal Donors
37. Nonabsorbable Corticosteroids Use in the Treatment of Gastrointestinal Graft-versus-Host Disease
38. Successful hematopoietic stem cell collection in patients who fail initial plerixafor mobilization for autologous stem cell transplant
39. Evaluating the effects of lenalidomide induction therapy on peripheral stem cells collection in patients undergoing autologous stem cell transplant for multiple myeloma
40. Aprepitant for prevention of nausea and vomiting secondary to high-dose cyclophosphamide administered to patients undergoing autologous peripheral blood stem cells mobilization: a phase II trial
41. Interim Analysis of a Pilot Study: Flu/Mel/TBI Peripheral Blood HLA-Haploidentical Stem Cell Transplantation with Post-Transplant Cyclophosphamide and Bortezomib (Cy2Bor3)
42. Mortality Predictors in Solid Organ Transplant Associated Graft Versus Host Disease. Single Center Experience
43. Lymphoblastic Leukemia/Lymphoma Following Lenalidomide Maintenance for Multiple Myeloma: Two Cases T and B
44. Cytomics, ECP and GVHD: A Pilot Study
45. Busulfan Kinetics and Chimerism Dynamics during Early Post-Transplant Period: An Update
46. Acute patient‐reported outcomes in B‐cell malignancies treated with axicabtagene ciloleucel
47. Collection of Peripheral Blood Progenitor Cells in One Day is Associated with Decreased Donor Toxicity compared to Two Days in Unrelated Donors
48. High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot study
49. 422 - A Single Institution Randomized Clinical Trial Evaluating Ciprofloxacin Versus Levofloxacin As Antibacterial Prophylaxis for Patients Receiving Hematopoietic Stem Cell Transplantation
50. 173 - Modeling Risk of Atrial Fibrillation in Stem Cell Transplant
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.